1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARIES
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISE IN THE INCIDENCE OF DIABETES
3.2.2. INCREASE IN HEALTHCARE EXPENDITURE
3.2.3. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
3.2.4. TECHNOLOGY INTEGRATION
3.2.5. INCREASING CGMS AND SMBG AFFORDABILITY
3.2.6. TECHNOLOGICAL ADVANCES IN GMS DEVICES
3.2.7. AWARENESS AMONG THE GENERAL POPULATION
3.3. KEY RESTRAINTS
3.3.1. HINDRANCE FROM GOVERNMENT REGULATIONS
3.3.2. INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES
3.3.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
3.3.4. INTENSE COMPETITION AMONG VENDORS
3.3.5. INACCURACY IN READING OF GMS DEVICES

4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. KEY BUYING CRITERIA
4.3. REGULATION OF BLOOD SUGAR
4.4. VALUE CHAIN ANALYSIS
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
4.7. KEY INVESTMENT INSIGHTS

5. CGMS MARKET BY COMPONENT TYPE
5.1. SENSORS
5.2. TRANSMITTER AND RECEIVERS
5.3. INTEGRATED INSULIN PUMPS

6. CGMS MARKET BY END-USER
6.1. HOME SETTINGS
6.2. DIAGNOSTICS AND CLINICAL
6.3. HOSPITAL

7. CGMS MARKET BY DEMOGRAPHICS
7.1. ADULT POPULATION (>14YEARS)
7.2. CHILD POPULATION (?14YEARS)

8. SMBG MARKET OVERVIEW

9. SMBG MARKET BY COMPONENT TYPE
9.1. TEST STRIPS
9.2. GLUCOSE METER
9.3. LANCETS

10. SMBG MARKET BY END USER
10.1. HOME SETTINGS
10.2. CLINICAL
10.3. HOSPITAL

11. SMBG MARKET BY APPLICATION
11.1. TYPE 1 DIABETES
11.2. TYPE 2 DIABETES
11.3. GESTATIONAL DIABETES

12. GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1. THE UNITED STATES
12.1.1.1. THE UNITED STATES HEALTH AND HEALTHCARE
12.1.1.2. THE UNITED STATES PHARMACEUTICAL MARKET
12.1.2. CANADA
12.1.2.1. CANADA HEALTH AND HEALTHCARE
12.1.2.2. CANADA PHARMACEUTICAL MARKET
12.1.2.3. CANADA DIABETES MARKET
12.2. EUROPE
12.2.1. GERMANY
12.2.1.1. GERMANY HEALTH AND HEALTHCARE
12.2.1.2. GERMANY PHARMACEUTICAL MARKET
12.2.2. THE UNITED KINGDOM
12.2.2.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
12.2.2.2. THE UNITED KINGDOM HEALTHCARE PROVISION
12.2.2.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
12.2.2.4. THE UNITED KINGDOM PHARMACEUTICALS
12.2.3. FRANCE
12.2.3.1. FRANCE HEALTH AND HEALTHCARE
12.2.3.2. FRANCE HEALTHCARE PROVISION
12.2.4. RUSSIA
12.2.4.1. RUSSIA HEALTH AND HEALTHCARE
12.2.4.2. RUSSIA PHARMACEUTICAL SERVICES
12.2.5. ITALY
12.2.5.1. ITALY HEALTH AND HEALTHCARE
12.2.5.2. ITALY HEALTHCARE PROVISION
12.2.5.3. ITALY PHARMACEUTICAL MARKET
12.2.6. BELGIUM
12.2.7. POLAND
12.2.8. REST OF EUROPE (ROE)
12.3. ASIA PACIFIC
12.3.1. CHINA
12.3.1.1. CHINA HEALTH AND HEALTHCARE
12.3.1.2. CHINA PHARMACEUTICAL MARKET
12.3.1.3. CHINA DIABETES MARKET
12.3.1.4. MARKET TRENDS
12.3.2. INDIA
12.3.2.1. INDIA HEALTH AND HEALTHCARE
12.3.2.2. INDIA REGULATORY CHANGES
12.3.2.3. INDIA PHARMACEUTICAL MARKET
12.3.2.4. INDIA DIABETES MARKET
12.3.3. AUSTRALIA
12.3.3.1. MARKET TRENDS
12.3.4. JAPAN
12.3.4.1. JAPAN HEALTH AND HEALTHCARE
12.3.4.2. JAPAN PHARMACEUTICAL MARKET
12.3.4.3. JAPAN DIABETES MARKET
12.3.4.4. MARKET TRENDS
12.3.5. SOUTH KOREA
12.3.5.1. MARKET TRENDS
12.3.6. INDONESIA
12.3.6.1. MARKET TRENDS
12.3.7. MALAYSIA
12.3.7.1. MARKET TRENDS
12.3.8. PHILIPPINES
12.3.8.1. MARKET TRENDS
12.3.9. THAILAND
12.3.9.1. MARKET TRENDS
12.3.10. VIETNAM
12.3.10.1. MARKET TRENDS
12.3.11. REST OF APAC
12.4. REST OF WORLD
12.4.1. LATIN AMERICA
12.4.1.1. BRAZIL HEALTH AND HEALTHCARE
12.4.1.2. BRAZIL PHARMACEUTICAL MARKET
12.4.1.3. MEXICO HEALTH AND HEALTHCARE
12.4.1.4. MEXICO PHARMACEUTICAL MARKET
12.4.2. MIDDLE EAST AND AFRICA

13. COMPANY PROFILES
13.1. ABBOTT
13.2. APEX BIOTECHNOLOGY CORPORATION
13.3. ARKRAY INC
13.4. ASCENSIA
13.5. B BRAUN MELSUNGEN AG
13.6. BECTON DICKINSON AND COMPANY
13.7. DEXCOM
13.8. GLYSENS INC
13.9. INSULET CORP
13.10. I-SENS INC
13.11. JOHNSON AND JOHNSON
13.12. MEDTRONIC
13.13. MOREPEN LABORATORIES LTD
13.14. NEMAURA MEDICAL INC
13.15. ROCHE DIAGNOSTICS
13.16. SENSEONICS INC
13.17. TANDEM DIABETES CARE
13.18. TERUMO
13.19. WOCKHARDT
13.20. YPSOMED